• Milestone Pharma
    Milestone Pharma
    • About Us
      • Leadership Team
      • Board of Directors
      • Careers
      • Contact Us
    • Areas of Focus
      • Paroxysmal supraventricular tachycardia (PSVT)
      • Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
    • Research & Development
      • Etripamil
      • Publications
      • Clinical Trials
      • Patient Access
    • Investors & Media
      • News & Events
      • Stock Information
      • Financial Information
      • Corporate Governance
      • Investor Resources
Milestone Pharma
  • About Us
    • Leadership Team
    • Board of Directors
    • Careers
    • Contact Us
  • Areas of Focus
    • Paroxysmal supraventricular tachycardia (PSVT)
    • Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
  • Research & Development
    • Etripamil
    • Publications
    • Clinical Trials
    • Patient Access
  • Investors & Media
    • News & Events
    • Stock Information
    • Financial Information
    • Corporate Governance
    • Investor Resources
Close

Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial – The Lancet

  • June 20, 2023
  • Publication
  • By Debbie Everidge
  • 0 Comments
0
  • Milestone Pharma

Impact of Investigational, at-Home, Self-administered, Intranasal Etripamil on the Need for Additional Medical Intervention in Patients With Supraventricular Tachycardia

  • May 31, 2023
  • Publication
  • By Debbie Everidge
  • 0 Comments
0
  • Milestone Pharma

Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Presentation

  • May 26, 2023
  • Publication
  • By Debbie Everidge
  • 0 Comments
0
  • Milestone Pharma

Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Poster

  • May 26, 2023
  • Publication
  • By Debbie Everidge
  • 0 Comments

Potential New Therapeutic Option for the Treatment of SVT in Acute and Chronic Settings

  • May 4, 2023
  • Publication
  • By Debbie Everidge
  • 0 Comments

News in SVT Diagnosis and Management A. John Camm 16th April 2023 EHRA 2023

0
  • Milestone Pharma

First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301)

  • February 28, 2023
  • Publication
  • By Debbie Everidge
  • 0 Comments
0
  • Milestone Pharma

Self-administered Etripamil for Termination of Spontaneous Paroxysmal Supraventricular Tachycardia: Primary Analysis from the RAPID Study

  • November 7, 2022
  • Publication
  • By Debbie Everidge
  • 0 Comments
0
  • Milestone Pharma

Long-Term Outcomes of the NODE-302 Study. In the NODE-302 trial, the commonly recorded adverse events were nasal discomfort, nasal congestion, rhinorrhea, epistaxis, sneezing, cough, throat irritation, headache, and increased lacrimation. These adverse events were local and transient.

  • October 3, 2022
  • Publication
  • By Debbie Everidge
  • 0 Comments
0
  • Milestone Pharma

Rationale for and design of a multicenter, placebo-controlled, phase 3 study to assess efficacy and safety of intranasal etripamil for the conversion of paroxysmal supraventricular tachycardia

  • September 20, 2022
  • Publication
  • By Debbie Everidge
  • 0 Comments
0
  • Milestone Pharma

Very Low Efficacy of Vagal Maneuvers in Terminating Paroxysmal Supraventricular Tachycardia: Results From the NODE-301 Study

  • May 4, 2022
  • Publication
  • By Debbie Everidge
  • 0 Comments
  • 1
  • 2
  • >
Careers | Contact Us | Privacy Policy | Consumer Health Data Privacy Policy | Terms of Use
© 2025 Milestone Pharmaceuticals USA, Inc. All Rights Reserved.
  • English: United States
    • English: Canada
    • Français (French): Canada

Our website content is tailored by geographical region to comply with local regulatory requirements. Please select which country’s site you’d like to visit.

  • English: United States
  • English: Canada
  • Français (French): Canada